![](https://pulmonaryfibrosisnews.com/forums/wp-content/uploads/buddypress/groups/3/cover-image/5a4e47118f7b8-bp-cover-image.jpg)
![Group logo of Research and Development](https://pulmonaryfibrosisnews.com/forums/wp-content/uploads/group-avatars/3/5a74e55cdf131-bpfull.jpg)
Research and Development
This group unites PF patients, caregivers, researchers and medical professionals in a platform to... View more
AD-114 for IPF Reduces Disease Progression in Patient-derived Cells and Mice
-
AD-114 for IPF Reduces Disease Progression in Patient-derived Cells and Mice
An Australian study showed that AD-114, an investigative therapy for idiopathic pulmonary fibrosis (IPF) developed by AdAlta, prevented the infiltration of immune cells and collagen build-up in lung cells from IPF patients. AD-114 also reduced fibrotic injury in a mouse model.
The study, “Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis,” was published in the journal Scientific Reports.
Read more about this study here: “AD-114 for IPF Reduces Disease Progression in Patient-derived Cells and Mice, Study Shows“
What do you think about this study? Please share your thoughts below.
Sorry, there were no replies found.
Log in to reply.